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Opioid use in the UK has increased significantly over the last 20 years, with the 34% increase 
in number of opioid items dispensed in primary care dwarfed by the far greater rise of 127% 
in the oral morphine equivalent dose of those prescriptions [1]. It is now estimated that 5% of 
the UK population take opioids, while nearly 10% of the population take some form of 
dependence-forming medicines [2], a term that encompasses opioids, gabapentinoids, 
benzodiazepines and Z drugs. Dependence and addiction to opioids have been well-
recognised since Victorian times [3]. Prescribed opioid misuse is now a phenomenon seen in 
developed countries with the US and Canada being the worst affected [4]. Persistent 
postoperative opioid use has been identified as a contributor to this rise in opioid 
prescriptions. Studies, mainly undertaken in North America, have demonstrated that 0.6% to 
26% opioid-naïve patients, and 35% to 77% patients with previous opioid exposure, continue 
to take opioids for more than 3 months postoperatively when healing is complete and acute 
pain would have ceased [5]. 
In addition to patient factors, four main risk factors for prolonged opioid use have 
been identified: the use of modified-release opioid preparations; the duration of the initial 
opioid prescription (but, interestingly, not the dose); the use of repeat prescriptions; and 
surgery [5, 6].  This joint supplement from Anaesthesia and the British Journal of Surgery 
includes invited reviews on the current state of enhanced recovery after surgery (ERAS) and 
fast-track surgery [7], and on the use of scoring systems and patient-reported outcome 
measures (PROMS) to improve the quality of patient recovery [8]. All of these processes are 
commendable and have led to improvements in the quality of peri-operative care. However, 
has the introduction of fast-track surgery, scoring systems and the use of patient satisfaction 
outcome measures inadvertently contributed to the phenomena of persistent post-operative 
opioid use and opioid-induced ventilatory impairment? 
  
Long-acting opioids 
One of the cornerstones of ERAS is the use of analgesia to attenuate the stress response from 
surgery and promote restoration of function, thus expediting patient discharge from hospital 
[7]. At the same time that the benefits of enhanced recovery were being extolled, Purdue 
Pharma, and subsequently its subsidiaries, were beginning to promote the modified-release 
opioid, oxycodone (OxyContin®, Purdue Pharma, Stamford, CT, USA) [3]. Purdue Pharma’s 
subsidiaries and sister companies include Mundipharma and Napp Pharmaceuticals. Studies 
were published that created a narrative that OxyContin® was essential in fast-track surgery 
[4, 9-11]. The study by Reuben et al. has been retracted since its disgraced author admitted 
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fabricating results in multiple studies in what has been acknowledged as one of the widest-
ranging cases of academic fraud [4]; while the study by Sunshine et al. was sponsored by 
Purdue Pharma [9]. The study by de Beer et al. [10] demonstrated the superiority of 
controlled-release oxycodone in promoting mobilisation after lower limb arthroplasty, 
reducing length of stay and costs, when compared with intravenous patient-controlled 
analgesia or epidural analgesia, while other placebo-comparison studies demonstrated the 
superiority of controlled-release oxycodone in reducing one or more of the following: pain 
scores; subsequent opioid consumption; length of stay and costs [4, 11]. Based on these 
studies, and with aggressive marketing by Purdue Pharma, modified-release oxycodone 
became, and continues to be, an integral part of many enhanced recovery programmes [4]. 
With the benefit of hindsight, it not surprising that the use of an oral opioid analgesic is 
superior to placebo or patient-controlled analgesia, with the requisite drips, pumps and 
supplemental oxygen, in promoting mobility and thus reduced length of stay. In 2007, Purdue 
Pharma were found guilty of perpetuating misleading claims that OxyContin® was superior 
to other opioids by not being addictive. Three senior executives were also found guilty and 
the company was ordered to pay costs and damages of over $600 million [3]. Purdue Pharma 
is now facing an avalanche of class action claims and has just filed for bankruptcy. Current 
evidence shows that not only is oxycodone just as addictive as other opioids, it is actually 
more likeable by patients with a higher abuse liability [12].  
As well as the use of modified-release opioid preparations being the strongest 
predictor of subsequent sustained opioid use [6], their use also carries similar risks to the use 
of a continuous opioid or patient-controlled analgesia (PCA) ‘background’ infusion in opioid-
naïve patients for causing opioid-induced ventilatory impairment [13, 14]. In 2018, the 
Australian and New Zealand College of Anaesthetists and its Faculty of Pain Medicine joined 
the US Food and Drug Administration (FDA), the American Pain Society and the American 
Academy of Pain Medicine in stating that modified-release opioid analgesics are not 
recommended for use in treating acute pain or postoperative pain [13]. This advice is also in 
alignment with the recommendations of the US Center for Disease Control and Prevention 
(CDC), who advise that, when opioids are used for acute pain, clinicians should prescribe the 
lowest effective dose of immediate-release opioids (i.e. not extended-release preparations) 
and should prescribe no greater quantity than needed for the expected duration of pain severe 
enough to require opioids [15]. Moreover, the CDC and the US OxyContin® product licence 
state that modified-release oxycodone should be reserved for use in patients for whom 
alternative treatment options (e.g. non-opioid analgesics or immediate-release opioids) are 
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ineffective, not tolerated, or would otherwise be inadequate to provide sufficient management 
of pain [13, 15]. Thus, the widespread and continued use of OxyContin as an integral part of 
enhanced recovery after surgery pathways can only be described as a pseudoaxiom (a false 
principle or rule handed down from generation to generation of medical providers and 
accepted without serious challenge or investigation). 
 
Unidimensional pain scores 
At the same time as Purdue Pharma were gaining a licence to market OxyContin, the 
American Pain Society introduced the “Pain as the Fifth Vital Sign” campaign. The premise 
was that pain scores should be recorded routinely on an inpatient’s chart and that unrelieved 
pain should be seen as a ‘red flag’ for escalation [3]. It is now recognised that this campaign 
encouraging repeated pain assessment using unidimensional scores, such as the numeric 
rating scale (NRS), contributed to the burgeoning use of opioids [3, 16], with some studies 
failing to find a significant improvement in acute pain management [17]. Aiming for ‘no 
worse than mild pain’ [18] using the NRS as a tool was associated with increased opioid use 
and opioid-induced over-sedation [19], despite the fact that opioids have relatively little 
effect on movement-related pain [20], a primary focus of ERAS programmes to hasten 
mobilisation.  
In 2017, the Joint Commission (the US’s healthcare regulatory agency) recognised the 
dangers of unidimensional pain scores in driving unrealistic patient expectations and 
subsequent opioid dependence and recommended the use of multimodal scoring systems that 
include restoration of function, rather than reliance on unidimensional pain intensity scales to 
guide inpatient administration of opioids [21]. Subsequently, the “Pain as the Fifth Vital 
Sign” campaign has been discredited and is no longer being promoted [ 16], and the 
American Pain Society has been inundated with lawsuits over its links to opioid 
pharmaceutical companies and dissolved due to bankruptcy in June 2019. 
 
Opioid-induced ventilatory impairment 
As well as prescribed opioids being a risk factor for persistent post-operative opioid use, it is 
increasingly being recognised that prescribed opioids are a major cause of death or hypoxia 
caused by opioid-induced ventilatory impairment both in hospital and in the community [15]. 
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Whilst risk factors such as obstructive sleep apnoea, use of modified-release opioid 
preparations, increased sensitivity to opioids with age and concurrent use of sedatives such as 
gabapentinoids have been identified, many instances of opioid-induced ventilatory 
impairment occur in people with no risk factors. More worrisome is that standard track and 
trigger tools are not sensitive enough to provide early warning of impending opioid-induced 
ventilatory impairment. Therefore, the Australian and New Zealand College of Anaesthetists 
and its Faculty of Pain Medicine [14] have recommended that: opioids should not be titrated 
to unidimensional pain scores alone; slow-release opioids should be avoided; for opioid naïve 
patients, initial doses of opioid should be based on the patient’s age; and there must be 
regular assessment of a patient’s level of sedation whenever opioids are administered. 
 
Patient satisfaction 
In 2001, the Institute of Medicine in the USA deemed that the US health delivery system did 
not provide consistent, high-quality medical care to all people. Subsequently, the US 
Congress directed the Centre for Medicare and Medicaid Services to design a patient 
satisfaction survey to promote adoption of best practice. Failure to comply led to financial 
penalties. Three of the 22 questions concerned pain management: (1) During this hospital 
stay, did you need medicine for pain? (2) During this hospital stay, how often was your pain 
well controlled? (3) During this hospital stay, how often did hospital staff do everything they 
could to help you with your pain? 
As a result many clinicians felt obliged to administer more opioids than necessary in 
order to satisfy the patient reported satisfaction scores, and these specific patient reported 
outcome measures are now being removed from the US’s Hospital Consumer of Healthcare 
Providers and Systems Survey [22].  
 
Addiction 
These three pseudoaxioms pale into insignificance when compared with the fact that for over 
three decades, drug companies and doctors promoted the false concept that addiction to 
prescribed opioids is rare. This particular medical myth was based on a single letter 
comprising five sentences that was published in 1980, entitled: “Addiction rare in patients 
treated with narcotics”. In 2017, a bibliometric analysis identified that it had been cited 608 
times, with 439 of these publications citing it as evidence that addiction was rare in patients 
(including those with chronic pain) treated with opioids. Thus, this frequently and uncritically 
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cited letter created a narrative that allayed prescribers’ concerns about the risk of addiction 
with opioid therapy [23]. 
 
In summary, these various pseudoaxioms have had unintended consequences and have 
directly contributed to the dual issue of persistent post-operative opioid use and opioid-
induced ventilatory impairment. To promote the safe development of recovery after surgery, 
and reduce the risk of both prolonged postoperative opioid use and ventilatory impairment, 
we need to apply the lessons from North America and Australasia and encourage 
multidisciplinary care with multimodal analgesia, both in hospital and at home [24]. Surgical 
analgesic regimens need to be constructed using the concept of procedure-specific pain 
management, with increased use of regional anaesthesia techniques when appropriate [25], 
rather than relying on the World Health Organization’s pain ladder that was devised for the 
treatment of end-of-life cancer pain. Additional opioid analgesia needs to be titrated to 
function, not purely unidimensional pain intensity scores, with immediate-release 
formulations of opioids based on patients’ age, with no place for the routine use of modified-
release opioid preparations [14]. All patients on opioids need to be carefully monitored for 
signs of opioid-induced ventilatory impairment and over-sedation. Discharge analgesia needs 
more thought than it has received previously, with procedure-specific guidance determining 
the amount of analgesia a patient is given, with non-opioids as well as limited opioids. 
Additional education to medical and nursing staff will be required to ensure compliance. In 
addition, patients must be taught how to use, wean and dispose of their post-discharge 
analgesia safely, and provision must be made to identify those who are requesting repeat 
opioid prescriptions, either to address their persistent pain or to tackle inappropriate opioid 
continuation [24]. Through good intentions, postoperative pain management has left patients 
vulnerable to opioid risk; clinicians’ acknowledgement and awareness of that risk, together 
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